1 citations
,
May 2026 in “Journal of Dermatological Treatment” This case report suggests that starting selective Janus kinase 1 inhibition may improve alopecia in a patient with rheumatoid arthritis who was not responding to TNF-α inhibitor therapy and corticosteroids.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
In this study, researchers developed a computational method called iEdgePathDDA that prioritizes anticancer drug candidates by analyzing changes in gene interactions, demonstrating superior performance compared to existing methods across colorectal, breast, and lung cancer datasets.
1 citations
,
November 2024 in “Blood” This study found that inhibiting the PI3Kδ enzyme in murine models of cutaneous chronic graft-versus-host disease (cGVHD) reduced skin scores and fibrosis, prevented pathogenic lymphoid structures, and improved survival, suggesting it as a promising therapeutic approach to address the disease's hypoxic pathophysiology.
In this clinical trial, patients with lichen planopilaris treated with the oral TYK2 inhibitor deucravacitinib showed significant improvement in PGA, LPPAI, and Skindex-16 scores over 24 weeks, with transcriptomic analyses indicating decreased inflammatory and immune pathway activity post-treatment.